A5008177303- Sexual function and dysfunction studies
- Genital Health and Disease
- Sexual Differentiation and Disorders
- Hormonal and reproductive studies
- Male Reproductive Health Studies
- Lung Cancer Treatments and Mutations
- Sexuality, Behavior, and Technology
- Glioma Diagnosis and Treatment
- Platelet Disorders and Treatments
- Urinary Bladder and Prostate Research
- Radiomics and Machine Learning in Medical Imaging
- Cancer Genomics and Diagnostics
- Reproductive tract infections research
- Statistical Methods in Clinical Trials
- Reproductive Health and Technologies
- Pelvic floor disorders treatments
- Lung Cancer Research Studies
- Urological Disorders and Treatments
- Acute Lymphoblastic Leukemia research
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Health Systems, Economic Evaluations, Quality of Life
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Reproductive Health and Contraception
- Meta-analysis and systematic reviews
Cancer Research UK Clinical Trials Unit
2015-2025
University of Birmingham
2015-2025
Genomics (United Kingdom)
2022-2024
Mayo Clinic in Arizona
2018-2020
University of Minnesota Rochester
2017-2019
WinnMed
2017-2019
Mayo Clinic in Florida
2017-2018
University of Bristol
2012-2015
NIHR Bristol Cardiovascular Biomedical Research Unit
2013
Johns Hopkins University
2000
Abstract There are no current stratified medicine options for STK11-deficient NSCLC. STK11 loss mediates mTORC activation, GLUT1 up-regulation and increased glycolysis. This metabolic reprogramming might represent a therapeutic vulnerability targetable with mTORC1/2 inhibition. In arm B2 of the National Lung Matrix Trial 54 patients NSCLC received vistusertib, which 49 were (30 KRAS mutation (B2D), 19 without (B2S)). Objective response (OR) durable clinical benefit (DCB) rates 95% credible...
Intravenous ribavirin was provided non-selectively for investigational open-label use among persons with suspected hantavirus pulmonary syndrome (HPS) in the United States between 4 June 1993 and 1 September 1994. Therapy initiated prior to laboratory confirmation of infection because most deaths from HPS occur within 48 h hospitalization. Thirty patients confirmed HPS, 105 without 5 adequate diagnostic testing were enrolled. This observational study arguably provides complete information...
Abstract Background Glioblastoma (GBM) is the most common adult malignant brain tumour, with an incidence of 5 per 100,000 year in England. Patients tumours showing O 6 -methylguanine-DNA methyltransferase (MGMT) promoter methylation represent around 40% newly diagnosed GBM. Relapse/tumour recurrence inevitable. There no agreed standard treatment for patients GBM, therefore, it aimed at delaying further tumour progression and maintaining health-related quality life (HRQoL). Limited clinical...
Patients with head and neck squamous cell carcinoma locally advanced disease often require multimodality treatment surgery, radiotherapy and/or chemotherapy. Adjuvant concurrent chemotherapy is offered to patients high-risk pathological features postsurgery. While cure rates are improved, overall survival remains suboptimal has a significant negative impact on quality of life.Cell cycle checkpoint kinase inhibition promising method selectively potentiate the therapeutic effects...
9542 Background: The clinical activity of pazopanib, a multi-targeted tyrosine kinase inhibitor, was evaluated in metastatic Merkel Cell Carcinoma (MCC) following case report demonstrating benefit phase II trial. Methods: Patients with histologically confirmed unresectable MCC received pazopanib at starting dose 800mg or 600mg daily, as clinically indicated, written informed consent. Chemotherapy pre-treated naïve patients were eligible. This single arm, multi-center, UK, trial using Simon...
Abstract Background Kaposi sarcoma (KS) is the commonest HIV-associated malignancy. It caused by co-infection with herpesvirus (KSHV), which upregulates MAPK pathway. The aim of SCART trial was to identify a safe dose for MEK inhibitor selumetinib in combination antiretroviral therapy (ART) and establish evidence combination’s efficacy. Methods prospective, single arm, open-label, multi-centre, phase I/II trial, recruiting from four UK centres. Eligible patients were HIV positive,...
Abstract Background A randomized, controlled clinical trial evaluating the efficacy of RestoreX traction therapy in men with Peyronie’s disease (PD) has been completed, 3-month results previously reported. The present study presents outcomes from open-label and follow-up phases original trial. Aim To report 6-month (open-label phase) 9-month (follow-up a (NCT03389854). Methods randomized was performed 2017 to 2019 110 all-comer PD. Men were 3:1 (PTT) or no (control) for 3 months, followed by...
Abstract Background Late-phase platform protocols (including basket, umbrella, multi-arm multi-stage (MAMS), and master protocols) are generally agreed to be more efficient than traditional two-arm clinical trial designs but not extensively used. We have gathered the experience of running a number successful together present some operational recommendations. Methods Representatives six UK trials units with in late-phase attended 1-day meeting structured discuss various practical aspects...
Background Formation of filopodia and other shape change events are vital for platelet hemostatic function. The mechanisms regulating formation by platelets incompletely understood however. In particular the small GTPase responsible initiating remains elusive. canonical pathway involving Cdc42 is not essential in mouse platelets. Rif (RhoF) provides an alternative route to generation cell types expressed both human Hypothesis/Objective We hypothesized that might be generating generated a...
Pre-clinical studies suggest AZD1775, a WEE1 kinase inhibitor, potentiates the activity of various chemotherapeutic agents.
Introduction Event-free survival rates at 15 years for paediatric patients with relapsed/refractory acute lymphoblastic leukaemia (ALL) are 30%–50%, 5-year adult only 20%. Many newly diagnosed and relapsed ALL harbour somatic RAS-signalling activation mutations. Induction therapy involves steroids, preclinical data suggesting the combination of dexamethasone MEK1/2 inhibitor, selumetinib (ARRY-142886) has a synergistic anticancer effect. Methods analysis The SeluDex trial is an...